Product Overview
[Drug Name]
Generic Name: Trimetazidine Hydrochloride Tablets
Trade Name: Xavier
English Name: Trimetazidine Dihydrochloride Tablets
Chinese Pinyin: Yansuan Qumeitaqin Pian
[Ingredients]
Ingredients: The active ingredient of this product is trimetazidine hydrochloride, chemical name: 1-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride, molecular formula: C₁₄H₂₂N₂O₃₂HCL, molecular weight: 339.3
[Properties]
This product is a film-coated tablet, which appears white after removal of the film coating.
[Indications]
Preventive treatment of angina attacks, adjunctive symptomatic treatment of vertigo and tinnitus.
[Dosage and Administration]
Oral administration: 40-60 mg/24 hours; one tablet 2-3 times daily, taken with a glass of water during meals. All patients should take this drug strictly according to their doctor's prescription.
[Adverse Reactions]
A very small number of patients may experience gastrointestinal discomfort (nausea and vomiting).
[Contraindications]
This drug is contraindicated in patients with allergies to any of its components. It is generally not recommended during breastfeeding (see [Use in Pregnant and Breastfeeding Women]).
[Precautions]
This drug is not intended for symptomatic treatment of angina pectoris or initial treatment of unstable angina or myocardial infarction. It should not be used for treatment before or during the first few days after hospitalization. During an angina attack, coronary artery disease should be reassessed, and treatment adjustments (medication and possible revascularization) should be considered.
[Use in Special Populations]
Precautions for Pediatric Use:
The safety and effectiveness of this drug in children have not been established.
Precautions for Pregnancy and Breastfeeding:
1. The risk of teratogenicity cannot be completely ruled out. For safety reasons, this drug should be avoided during pregnancy.
2. Effects of the Drug on Breastfeeding: It is unknown whether this drug is excreted in breast milk. Breastfeeding is recommended during treatment.
Precautions for Elderly Patients:
See other sections below or follow your doctor's advice.
[Drug Interactions]
To avoid potential interactions between different medications, you must inform your doctor or pharmacist of any other treatments you are taking.
[Pharmacological Actions]
Antianginal drugs. They have antagonistic effects on adrenaline, norepinephrine, and vasopressin, reducing vascular resistance, increasing coronary and circulatory blood flow, and promoting myocardial metabolism and energy production. They also reduce myocardial oxygen consumption, thereby improving the balance between myocardial oxygen supply and demand. They also increase tolerance to cardiac glycosides. Controlled trials in patients with angina have shown: 1. This drug increases exercise test tolerance, delays exercise-induced myocardial ischemia, and reduces ischemia starting on day 15 of treatment without causing hemodynamic changes. 2. It limits rapid blood pressure fluctuations without causing significant changes in heart rate, significantly reducing the frequency of angina attacks. 3. It significantly reduces the need for nitroglycerin. Trimetazidine mechanism of action: The effect on ischemic myocardium may be direct cytoprotection. By preserving energy metabolism within ischemic cells and preventing a decrease in intracellular ATP levels, it maintains a stable intracellular environment while ensuring the proper function of ion pumps and the normal transmembrane sodium-potassium pump transport. This reduces intracellular acidosis and prevents the accumulation of sodium and calcium within myocardial cells, protecting cell contractility and limiting cell lysis and endothelial damage caused by oxygen free radicals.
[Storage] Store tightly in a dry place.
[Strength] 20 mg
[Packaging] 20 mg/tablet, 30 tablets/box
[Expiry Date] 24 months.
[Approval Number] National Medicine Standard H20065167
[Manufacturer] Company Name: Beijing Wansheng Pharmaceutical Co., Ltd.
